Deepak Jasani, Head of Retail Research, HDFC Securities

Indian benchmark equity indices suffered sharp swings on either side on March 25 as the March series F&O expiry had a volatile close. Nifty has seen acceleration in its downtrend after it breached the crucial level of 14,788. In the process it has filled the upgap made on Feb 02. A sharp rise in COVID-19 cases globally and reports of lockdown seems to have eroded investors' risk appetite. Hardening bond yields, and rising inflation are also not helping matters. Although the indicators/oscillators are oversold, we are not sure as to whether a bounce will come from these levels or after falling to 13,966.

Mar 25, 2021 4:14 PM

Ajit Mishra, VP - Research, Religare Broking

Markets traded under pressure on the F&O expiry day and lost over one and a half percent. The selling pressure has intensified in the last couple of sessions owing to weak global cues and concerns over the second wave of COVID cases. On the benchmark front, Nifty has next critical support at 14,000 levels however rebound in the banking index might result in some bounce or consolidation first. Amid all, we reiterate our cautious stance and suggest traders to focus more on risk management.

Mar 25, 2021 4:11 PM

Manish Hathiramani, Proprietary Index Trader and Technical Analyst, Deen Dayal Investments

The Nifty respected the support of 14,300-14,350 on a closing basis. However, if we break 14,300 on a closing basis, we will plummet further to levels closer to 13,600. On the upside, the resistance is at 14,900 and any upside correction can be utilized to short the index for newer targets on the downside.

Mar 25, 2021 3:59 PM

Mar 25, 2021 3:58 PM

Mar 25, 2021 3:52 PM

Mar 25, 2021 3:50 PM

Here are key stocks that moved the most on March 25

The Sensex ended 740 points lower at 48,440 while the Nifty fell 224 points to settle at 14,325.Get latest Market online at cnbctv18.com

Mar 25, 2021 3:45 PM

Market In March F&O Series

- March 2021 Series, The Worst Since March 2020 In Absolute Terms

- Sensex, Nifty & Nifty Bank Post The Biggest Series Fall In A Year

- Except IT & FMCG, All Sectoral Indices Give Negative Returns In March Series

- Coal India, GAIL, ONGC, Hero Moto, Tata Motors Top Nifty Losers In March Series

- Grasim, Infosys, UltraTech, JSW Steel, HCL Top Nifty Gainers This Series

Mar 25, 2021 3:43 PM

Market At Close

- Market Erases All The Gains Since Budget, Closes At Nearly 2-mth Lows

- Sensex, Nifty & Midcap Index Fall 2% Each; Nifty Bank Falls 1%

- All Sectoral Indices End Lower With Auto & Energy Being Top Losing Indices

- 44 Of 50 Nifty Stocks Are In The Red; IOC, Maruti, HUL, Tata Motors Top Losers

- Sensex Falls 740 Points To 48,440 & Nifty 225 Points To 14,325

- Nifty Bank Slips 287 Points To 33,006 & Midcap Index 476 Points To 22,859

- Market Breadth Favours Declines; Advance-Decline Ratio At 1:5

- BSE Companies Erase Market Cap Of More Than `4 Lakh Crore Today

Mar 25, 2021 3:40 PM

Closing Bell | Indian equity market extended losses to end sharply lower Thursday dragged by heavy selling across the board as worries over rising coronavirus cases in the country and the possibility of fresh restrictions spooked investors. The Sensex plunged 740.19 points, or 1.51 percent to 48,440.12, while the Nifty ended 224.50 points, or 1.54 percent lower at 14,324.90. Broader markets also fell for the day with the midcap and smallcap indices down over 2 percent each.

All sectors, barring metals, ended in the red with Nifty Energy down 3 percent. Nifty Auto also lost 2.7 percent, while Nifty IT and Nifty FMCG fell over 2 percent each. Meanwhile, the banking and financial indices lost around a percent each. On the Nifty50 index, IOC, Maruti Suzuki, Coal India, Bharti Airtel and Hindustan Unilever led the losses while Tata Steel, Dr Reddy's Laboratories, ICICI Bank, HDFC and Larsen & Toubro were the top gainers.

Mar 25, 2021 3:39 PM

It's a bull market correction; IT, infra, private banks to do well: experts

The Indian equity market fell sharply as rising COVID cases and worries over lockdowns in several cities weighed on investor sentiment. Selling in financials and autos stocks dragged the benchmark indices, Sensex and Nifty near two-week low levels. “The market sell-off is a confluence of local factors amid the sudden spike in COVID infections. Though thankfully the mortality rate is still quite low and we do have the vaccination drive been accelerated. So hopefully the negative news won’t last as long as the last COVID infection wave,” said Mihir Vora, Director & CIO of Max Life Insurance. He noted that there was a consolidation and correction in the global markets given the strength in the dollar, given the rise in the US bond yields. Watch here.

Mar 25, 2021 3:21 PM

Jubilant-Popeyes deal: Edelweiss’ Roy feels Jubilant share can hit Rs 3,575

Jubilant Foodwork shares trading lower after climbing 4 percent early in the day on news of the company signing a master franchise and development agreement with PLK APAC Pte, to bring US fried…

Mar 25, 2021 3:02 PM

CLSA gives 'outperform' rating for Bandhan Bank; sets target price at Rs 390

Bokerage firm CLSA has given an 'outperform' rating for Bandhan Bank, stating that there is no mention of microfinance loan waivers in the Assam and West Bengal election manifestos. CLSA has set a price target of Rs 390 for the stock. The brokerage firm states that in the upcoming elections of Assam and West Bengal election manifestos largely refrained from promising microfinance loan waivers. In Assam, the manifesto refers only to enhancing income support to Rs 3,000 per month to a larger set of beneficiaries.

As highlighted by credit bureaus, Assam's overdue loans at more than 40 percent were higher than average due to political uncertainty, which should abate now. But the West Bengal overdue at about 40 percent on a system-level has been surprisingly high despite reduced political noise; so, it will be required to monitor if the absence of manifesto waiver announcements will lead to improved microfinance collections in Bengal. Continue reading.

Mar 25, 2021 2:45 PM

Motilal Oswal on Divi’s Laboratories

Divi’s Laboratories is well-placed to capitalize on the carotenoid opportunity too, with a 21 percents ales CAGR to Rs 8 billion expected over FY20–23, driven by healthy demand, integrated manufacturing, and doubled capacity. We value Divi’s Laboratories at 36x 12M forward earnings to arrive at target price of Rs 4,530. We reiterate Buy and see multiple growth levers –new product additions, strong chemistry skillset, efficient manufacturing capabilities, scale advantage in legacy molecules, minimal financial leverage, and sufficient cash available for new projects.

Mar 25, 2021 2:30 PM

Mar 25, 2021 2:15 PM

Load more